Research Paper Volume 14, Issue 16 pp 6668—6688
MicroRNA-148a induces apoptosis and prevents angiogenesis with bevacizumab in colon cancer through direct inhibition of ROCK1/c-Met via HIF-1α under hypoxia
Figure 6. miR-148a suppresses VEGF secretion and the angiogenesis of bevacizumab in HT29 colon cancer cells under hypoxic conditions. (A) Human umbilical vein endothelial cell tube formation assay in four HT29 cell lines (HT29, HT29 + bevacizumab, HT29-miR-148a, and HT29-miR-148a + bevacizumab); (B) Both miR-148a and bevacizumab significantly inhibited human umbilical vein endothelial cell formation (all P < 0.001); (C) VEGF expression levels in HT29, HT29 + bevacizumab, HT29-miR-148a, and HT29-miR-148a + bevacizumab as obtained using Western blotting under hypoxia; (D) miR-148a significantly inhibited VEGF secretion as shown in the Western blotting analysis (P = 0.004) but not in HT29 + bevacizumab cells. β-Actin served as an internal control.